Law firm Kaplan Fox & Kilsheimer LLP has announced it is investigating potential securities violations involving Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company. The investigation follows Fulcrum's June 1, 2026 announcement that it was discontinuing its pociredir program for sickle cell disease, after the FDA raised serious concerns about the drug's benefit-risk profile. Fulcrum shares fell 51.09% the following trading session, from $6.42 to $3.14 per share, a decline of $3.28 per share. Investors who suffered losses are being invited to contact the firm.
Key Points
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is the subject of a securities investigation by Kaplan Fox & Kilsheimer LLP
- Fulcrum discontinued its pociredir sickle cell disease program after the FDA found no viable regulatory path forward
- FULC shares dropped 51.09%, from $6.42 to $3.14, on June 2, 2026 following the announcement
- Investors who suffered losses in FULC are being encouraged to contact Kaplan Fox regarding the investigation
Pociredir Program Discontinued After FDA Raises Malignancy Concerns
Fulcrum Therapeutics announced after market close on June 1, 2026, that it was discontinuing its pociredir program for sickle cell disease. The company stated that meeting minutes from end-of-phase interactions with the FDA reflected heightened concerns over pociredir's benefit-risk profile. Those concerns stemmed from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026. The FDA subsequently concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk, leaving Fulcrum with no viable regulatory path forward for pociredir.
FULC Share Price Collapses More Than Half in a Single Session
Following the June 1, 2026 after-hours disclosure, Fulcrum Therapeutics shares closed at $3.14 on June 2, 2026, down from the prior session's close of $6.42 — a decline of $3.28 per share, or 51.09%. The sharp single-session drop reflects the market's reaction to the complete loss of a lead clinical program. Investors who held positions in FULC ahead of the announcement and sustained losses may be affected by the ongoing Kaplan Fox investigation into potential securities violations connected to the events surrounding the pociredir discontinuation.
Kaplan Fox Securities Investigation Targets Potential Investor Losses
Kaplan Fox & Kilsheimer LLP, founded in 1956, is described in the announcement as a nationally recognised firm focused on complex litigation with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. The firm states it has recovered more than $10 billion for clients across securities, antitrust, and consumer protection cases. The investigation into Fulcrum Therapeutics centres on potential securities violations, and the firm is seeking to hear from investors who suffered losses or who possess information relevant to the matter. The release notes that contacting the firm does not create an attorney-client relationship.




Please wait processing your request...